Business Wire

FPT-SOFTWARE

15.3.2024 10:12:32 CET | Business Wire | Press release

Share
FPT Expands Global Presence with New Subsidiary in Dalian, China

Global IT company FPT announced the inauguration of its new extension in China, FPT Dalian. Leveraging its highly skilled workforce with diverse language proficiencies, the new subsidiary is poised to enhance support to companies in Japan and China, with a future direction of broadening its global customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240315542507/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The inauguration was attended by government representatives, Japanese and Chinese partner companies, FPT executives, and other distinguished guests. (Photo: Business Wire)

The strategic move allows FPT to gain access to a high-quality talent pool of over 200,000 Japanese-proficient IT engineers and a network of top-notch universities with ICT training, serving its initial focus on supporting existing Japanese customers. Combined with FPT's well-established position in Japan and global resources, it can extend support and provide end-to-end digital solutions to other Chinese businesses and thousands of Japanese companies operating here.

Located in the high-technology zone for leading enterprises, such as Canon, Amazon, and KPMG, this new office allows the firm to stay closer to its existing customers and further expand its Chinese presence.

According to Mdm. Chu Thi Thanh Ha, Chairwoman of FPT Software (a subsidiary of FPT), FPT Dalian, not only enables the company to further accompany businesses in the region but also serves as a commitment to the governments of China, Japan, and Vietnam. “As a leading IT firm in Vietnam, we aim to serve as a bridge for economic corporations between China, Japan, and Vietnam. We believe FPT Dalian can actively help strengthen relationships and promote cross-border collaborations among companies here.” she pledged.

According to FPT Dalian CEO Pham Thanh Tuan, the firm plans to expand its local workforce to 2,000-3,000 employees within the next three to five years. To realize this goal, it is committed to close collaborations with universities and other educational institutions in Dalian to provide ICT training and career opportunities.

The establishment of FPT Dalian also received support from the local authorities, marked by Dalian government representatives' recent visit to FPT. Here, the government delegation expressed strong support for FPT's Dalian branch and its vision for the city's socioeconomic development.

After nearly two decades of operating in Japan, FPT Japan has become one of Japan's largest foreign-invested tech firms in terms of human resources. With a workforce of 3,000 onsite employees, nearly 15,000 employees working from overseas, 16 local offices and innovation hubs, FPT Japan has provided services and solutions to over 450 clients worldwide. The company is also recognized for excellent employee benefits and workplace happiness, earning accolades such as Best Workplaces in Asia, Best Places to Work in Japan, and Best Places to Work for Women in Japan.

Before FPT Dalian, FPT has developed a solid presence in China, with offices in Shanghai and Nanning, launched in 2017 and 2023, respectively, and has formed strategic partnerships with key Chinese players in the automotive and semiconductor sectors.

The new office is located at No.1, Hui Xian Yuan, Dalian Hi-tech Industrial Zone, Dalian, 116025, China.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240315542507/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye